Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced inducement equity awards granted on October 1, 2025 to 27 new non-executive employees under its 2025 Inducement Plan.
The awards, approved by the independent Compensation Committee consistent with Nasdaq Listing Rule 5635(c)(4), comprise options to purchase 1,602 shares and 10,973 time‑based restricted stock units (RSUs) in the aggregate. Option exercise price is $449.14 per share (closing price on grant date).
Vesting: options vest 25% at one year then 6.25% each quarter thereafter; RSUs vest in four equal annual installments. All vesting is conditioned on continued employment as of each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in MASH therapeutics, has announced equity inducement awards for 76 new non-executive employees under its 2025 Inducement Plan. The awards, approved by the company's Compensation Committee under Nasdaq Rule 5635(c)(4), include:
The grants consist of options to purchase 2,015 shares of common stock at $425.60 per share and 31,821 time-based restricted stock units. Options vest 25% after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced equity inducement awards for new employees. The company granted a total of 4,510 time-based restricted stock units to 17 new non-executive employees on September 1, 2025.
The awards, approved under Madrigal's 2025 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments. The vesting is contingent upon continued employment through each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced its upcoming participation in the Morgan Stanley 23rd Annual Global Health Care Conference. The presentation is scheduled for Monday, September 8, 2025, at 7:45 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has granted equity inducement awards to 11 new non-executive employees.
Under the company's 2025 Inducement Plan, the employees received a total of 6,940 time-based restricted stock units. These units will vest in four equal annual installments, subject to continued employment. The awards were approved by Madrigal's independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received European Commission approval for Rezdiffra (resmetirom), making it the first and only approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in the European Union.
The conditional marketing authorization is based on successful Phase 3 MAESTRO-NASH trial results, where 91% of patients treated with Rezdiffra 100 mg showed improvement or stabilization of liver stiffness at one year. The once-daily oral treatment targets approximately 370,000 diagnosed patients across Europe.
Madrigal plans to launch Rezdiffra in Europe starting with Germany in Q4 2025, with other EU countries, Iceland, Liechtenstein, and Norway to follow based on individual reimbursement procedures.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's presentation is scheduled for Tuesday, August 12, 2025, at 10:30 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in MASH therapeutics, announced the granting of equity inducement awards to 26 new non-executive employees under its 2025 Inducement Plan. The awards include options to purchase 1,984 shares at $302.17 per share and 9,727 time-based restricted stock units.
The equity grants, approved by Madrigal's independent Compensation Committee under Nasdaq Rule 5635(c)(4), include a vesting schedule where 25% of options vest after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest equally over four years, contingent on continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong Q2 2025 financial results, with Rezdiffra net sales reaching $212.8 million. The company achieved several significant milestones, including receiving a new U.S. patent extending Rezdiffra's protection until 2045, securing a $500 million senior secured credit facility, and obtaining a positive CHMP opinion for European approval.
Key financial metrics include cash position of $802.0 million as of June 30, 2025. Operating expenses were $260.0 million, with SG&A expenses at $196.9 million and R&D expenses at $54.1 million. The company expanded its pipeline through a global licensing agreement for an oral GLP-1 development candidate and presented promising two-year F4c MASH clinical data at EASL Congress.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. The deal involves an upfront payment of $120 million and potential milestone payments up to $2 billion, plus royalties.
The agreement aligns with Madrigal's strategy to develop combination treatments for MASH (Metabolic dysfunction-Associated SteatoHepatitis), building upon their foundational therapy Rezdiffra™. Clinical development is planned to begin in first half of 2026. The combination aims to leverage GLP-1's weight loss benefits with Rezdiffra's fibrosis and lipid reduction capabilities in a once-daily oral formulation.